Photoacoustic nanodroplets for oxygen enhanced photodynamic therapy of cancer

Marvin Xavierselvan\textsuperscript{a}, Jason Cook\textsuperscript{b}, Jeanne Duong\textsuperscript{a}, Nashielli Diaz\textsuperscript{a}, Kimberly Homan\textsuperscript{b}, Srivalleesha Mallidi\textsuperscript{a,c,}\textsuperscript{*}

\textsuperscript{a} Department of Biomedical Engineering, Tufts University, Medford, MA 02155, USA
\textsuperscript{b} Nanohybrids Inc., Austin, TX 78744, USA
\textsuperscript{c} Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA 02114, USA

\textbf{A R T I C L E  I N F O}

\textbf{A B S T R A C T}

Photodynamic therapy (PDT) is a well-known cancer therapy that utilizes light to excite a photosensitizer and generate cytotoxic reactive oxygen species (ROS). The efficacy of PDT primarily depends on the photosensitizer and oxygen concentration in the tumor. Hypoxia in solid tumors promotes treatment resistance, resulting in poor PDT outcomes. Hence, there is a need to combat hypoxia while delivering sufficient photosensitizer to the tumor for ROS generation. Here we showcase our unique theranostic perfluorocarbon nanodroplets as a triple agent carrier for oxygen, photosensitizer, and indocyanine green that enables light triggered spatiotemporal delivery of oxygen to the tumors. We evaluated the characteristics of the nanodroplets and validated their ability to deliver oxygen via photoacoustic monitoring of blood oxygen saturation and subsequent PDT efficacy in a murine subcutaneous tumor model. The imaging results were validated with an oxygen sensing probe, which showed a 9.1 fold increase in oxygen content inside the tumor, following systemic administration of the nanodroplets. These results were also confirmed with immunofluorescence. In vivo studies showed that nanodroplets held higher rates of treatment efficacy than a clinically available benzoporphyrin derivative formulation. Histological analysis showed higher necrotic area within the tumor with perfluoropentane nanodroplets. Overall, the photoacoustic nanodroplets can significantly enhance image-guided PDT and has demonstrated substantial potential as a valid theranostic option for patient-specific photodynamic therapy-based treatments.

\textbf{1. Introduction}

Photodynamic therapy (PDT), a treatment modality that utilizes light energy and photosensitizer (PS) molecules, has been employed successfully to treat several malignant tumors such as brain tumors, oral cavity tumors and esophageal malignancies [1,2]. Particularly PDT is sought out for its highly localized effect and excellent post-therapy mucosal healing and recently PDT efficacy in treating T1-T2 early-stage oral cancer lesions has been demonstrated by us and several other groups [3–6]. It is common for large or late-stage tumors to encompass hypoxic regions, where typically the PDT process is ineffective as the generation of cytotoxic reactive oxygen species (ROS) requires oxygen to react with the PS molecule. Such a mechanism, referred to as Type-II PDT, is a common mode of action for many PS molecules used in the clinic currently; therefore, their efficacy is predominantly determined by the oxygen content in the photodynamic action vicinity [2,7].

Several studies have demonstrated poor outcomes using PDT with the Type-II PS molecules in hypoxic tumors [8,9], as with radiation and chemotherapy [9–12]. Increasing tumor oxygenation will improve the therapeutic efficacy of PDT while increasing tumor sensitivity for subsequent therapies. Previously, this shift on tumor oxygen content was achieved through hyperbaric oxygenation methods in which the
inhalation of pure oxygen leads to a decrease of hypoxic content within the tumor [13–15]. Unfortunately, inhaling excessive oxygen, i.e., overall systemic delivery, can have harmful side effects such as: seizures, progressive myopia, nuclear cataract, pulmonary edema, alveolar hemorrhage [16], interstitial fibrosis, retrolental fibroplasia and hypoglycemia [17,18]. Other methods such as oxygen-carrying nanoparticles or MnO2 nanoparticles have been developed to release oxygen inside the tumor, following either a change in pH [19] or reaction with H2O2 [20]. However, shortcomings of these nanoparticles include the absence of spatiotemporal triggering during oxygen delivery, lack of imaging contrast for real time monitoring, and inclusion of non-clinically approved optical contrast agents during fabrication. Few studies have utilized clinically approved ultrasound contrast agents (microbubbles) to deliver oxygen and drugs [21–25]. Nonetheless, microbubbles owing to their large size (1–10 µm) do not efficiently extravasate through leaky blood vessels to localize in the tumor region resulting in lower efficacy of delivering oxygen to the hypoxic regions [26,27]. The limitation of microbubbles led to the development of nanobubbles and nanodroplets as reviewed elsewhere [28]. Both have a size range of 40–200 nm and similar preparation methods. The distinction is that nanobubbles have gas cores (gas-liquid colloid) while nanodroplets have liquid cores (liquid-liquid colloid) [24,26,27]. In our study, we used nanodroplets fabricated with perfluorocarbons (PFCs) to deliver oxygen, PS and a photoacoustic (PA) contrast agent to the tumors. PFCs are particularly apt for carrying oxygen [29–31] as they have high oxygen solubility and carrying capacity [32,33], are biocompatible organic compounds [34] which are metabolically inert, and can be triggered remotely to deliver their contents [35–37]. Additionally, reports have shown that the lifetime of singlet oxygen (∆O2) in PFC is longer than in the cellular environment or in water [30]. Therefore, the advantage of using PFC nanodroplets for oxygen and PS delivery is that they both will be in the same vicinity for photodynamic action to occur, resulting in improved treatment outcomes [38,39].

In addition to co-delivery of oxygen and PS, another advantage offered by nanodroplets is the ability to spatiotemporally trigger the oxygen release while monitoring nanoparticle uptake and oxygenation changes in the tumor in real time. To facilitate these properties, we synthesized nanodroplets containing PFC and indocyanine green (ICG), an optical diagnostic agent that has peak light absorption in the near infrared (NIR) range. ICG is a clinically approved dye in medical diagnostics for measuring cardiac output, hepatic function and ophthalmic angiography [40]. Given its high absorption compared to endogenous chromophores such as blood and melanin, and its ability to generate heat when excited, ICG has been extensively used as a PA contrast agent for molecular imaging [41,42]. In addition to providing imaging contrast, ICG can also initiate PFC vaporization via laser irradiation at 808 nm, a wavelength at which ICG has high optical absorption compared to endogenous chromophores. The spatially localized laser irradiation in a particular region of interest initiates PFC vaporization leading to localized drug delivery [43]. Furthermore, the temporal control of drug release can be achieved by irradiating the PFC droplets at a time when the uptake of the PFC particles is maximum in the tumor region. Previous investigations observed that PFC loaded with ICG can act as a dual contrast agent for both ultrasound [34,44] and PA imaging [34]. Specifically, PA imaging is a hybrid imaging modality wherein the tissue is irradiated with nanosecond pulsed laser light [45]. Any absorbers in the light path transiently undergo thermoelastic expansion and contraction, generating an acoustic wave. The acoustic wave can be detected by an ultrasound transducer which, in turn, displays images of optical absorption within the tissue. PA imaging can provide information about the oxygen saturation (StO2) and total hemoglobin content (HbT) without the use of external contrast agents [46] since oxygenated and deoxygenated hemoglobin have optical absorption at different wavelengths [47]. As a result, PA imaging has been used along with PDT for monitoring the tumor and predicting the treatment outcomes [46].

In this study, we constructed nanodroplets specifically to enhance PDT in hypoxic tumors. The nanodroplets contain perfluoropentane (PFP) saturated with oxygen, ICG, and benzoporphyrin derivative (BPD) for PA-guided PDT (Fig. 1A). The presence of ICG in our nanodroplets enables the laser-triggered spatiotemporal delivery of oxygen for PDT while simultaneously providing contrast for PA imaging. The therapeutic aspect of our nanodroplets is attributed to BPD, an FDA approved drug for the treatment of subfoveal choroidal neovascularization. BPD and ICG do not impact each other’s performance when employed in optimal concentrations as we recently demonstrated [48]. Our in vitro and in vivo murine tumor model studies prove that PDT efficacy can be significantly improved with specific light-based triggering of ICG at its peak absorbance to deliver oxygen and the photosensitizer at the right place and the right time. The novel formulation of PFP nanodroplets...
described here encapsulates FDA approved PDT and imaging components and therefore, has tremendous clinical translation potential for oxygenating hypoxic tumors, not only for PDT, but also for other therapies such as radiation and chemotherapy whose efficacy can be enhanced in a hypoxic environment.

2. Material and methods

2.1. Synthesis of PFP nanodroplets

The PFP nanodroplets (shown in Fig. 1a) were formed using PFP in water emulsion. United States Pharmacopeia (USP) Reference Standard grade ICG (MilliporeSigma, Burlington, MA) was solubilized into chloroform using tertbutylammonium iodide (TBAI) (MilliporeSigma, Burlington, MA). A 1 mg/mL aqueous solution of ICG was mixed with a solution of 3 mg/mL TBAI in chloroform at a 1:3 vol ratio. After shaking at 100 rpm overnight, the chloroform phase containing ICG was extracted. A combination of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DSPE-mPEG), cholesterol (Avanti Polar Lipids, Alabaster, AL), ICG in chloroform, and benzoporphyrin derivative (MilliporeSigma, Burlington, MA) were added to a 100 mL round-bottom flask at a molar ratio of 88:2:3:2:5, respectively. After rotovaping for 2 h, the lipid cake was hydrated using water to yield a final lipid concentration of 10 mg/mL. To this solution, 0.25 mL of n-perfluoropentane (Exfluor, Round Rock, TX) for every 1 mL of hydrated lipid solution was added. The solution was sonicated in a bath sonicator for 10 s, followed by 1 min in an ice bath to minimize heating effects. This sonication procedure was repeated until the desired size distribution was achieved. Once synthesized, the particles were stored at 4 °C for up to 12 weeks before use. Oxygen was encapsulated into the PFP nanodroplets immediately prior to use. To accomplish this, the PFP nanodroplets were warmed to room temperature and oxygenated by gently bubbling the solution with 100% oxygen gas (1 liters/minute for 5 min). During this process some of the gas is dissolved into the liquid solution and is then captured by the liquid PFP in the nanodroplets. Because of liquid PFP’s high solubility of oxygen [33], the PFP nanodroplets retain the oxygen and do not release until the PFP is vaporized with laser irradiation.

2.2. Characterization of PFP nanodroplets

The size, size distribution, and zeta potential of PFP nanodroplets were characterized using the Dynamic Light Scattering (DLS) System (Zetasizer Nano ZS, Malvern Panalytical). UV Visible spectrophotometer (Evolution 300, Thermo Fisher Scientific) was used to measure the absorbance spectra of various PFP nanodroplets and quantify the concentration of BPD and ICG.

2.3. Photoacoustic imaging of PFP nanodroplets

PA imaging was performed using a Vevo 2100 LAZR Imaging System (VisualSonics, FUJIFILM) equipped with a 21 MHz LZ-250 ultrasound transducer. PA spectra and stability tests were conducted in a water tank containing polypropylene tubes filled with samples. PA spectral imaging was performed from 680 nm to 950 nm. The laser was calibrated prior to every experiment. The PFP particles were also imaged using the single wavelength pulsed irradiation at 800 nm (fluence of ~30 mJ) and 690 nm (fluence of ~25 mJ). The PA signals from the particles were quantified using Vevo Lab software (FUJIFILM VisualSonics). A region of interest (ROI) (1.45 mm² area) was drawn around the top half of the tube, maintaining the same parameters throughout the entirety of the analysis, across various solutions.

2.4. Singlet oxygen measurements

Singlet oxygen production was calculated using the commercially available Singlet Oxygen Sensor Green (SOSG) kit (Invitrogen). The SOSG was dissolved in methanol and the working solution was prepared in ultrapure water. Free BPD, BPD-PFP, ICG-PFP and BPD+ICG-PFP (with different loading ratios of BPD and ICG) nanodroplet solutions were diluted to a concentration of 5 µM in phosphate-buffered saline (PBS) supplemented with 10% FBS. The SOSG was added to the solutions at a concentration of 5 µM and the solutions were irradiated with a 690 nm laser at an irradiance of 150 mW/cm² and a total light dose of 20 J/cm². After irradiation, the SOSG fluorescence intensity was recorded using the Spectramax M5 plate reader using 460 nm excitation with a 515 nm cut-off filter and emission at 525 nm. For testing the efficiency of oxygen in carrying BPD-PFP nanodroplets to produce singlet oxygen in hypoxic conditions, nitrogen gas was flushed through the environment for 5 min to reduce the oxygen concentration. Following this, the solution was irradiated and SOSG fluorescence was measured.

2.5. Cell culture

Human Squamous Cell Carcinoma (FaDu Cells) were cultured in Eagle’s Minimum Essential Medium supplemented with 10% fetal bovine serum (FBS, Gibco) and 1% antibiotics (Penicillin and Streptomycin 1:1 v/v, Corning), and maintained at 37 °C and 5% CO₂. The cells were sub-cultured and used for experiments while they were in the exponential growth phase.

2.6. Cellular uptake and localization studies

For cellular uptake, FaDu cells were seeded in a 6 well plate at a density of 1.5 × 10⁵ per well. The following day, the cells were incubated with fresh cell culture media containing BPD-PFP and ICG-PFP at concentrations of 250 nM and 1000 nM, respectively. After 90 min of incubation, the media was removed, and cells were washed with ice cold PBS twice and lysed using 1% Triton X-100. The cell lysate was centrifuged to remove the precipitate and the lysate was used to measure the BPD and ICG fluorescence using the Fluoromax 3 (Horiba) and converted to moles of PS based on appropriate standards. Bicinchoninic acid assay was performed to calculate the cellular protein and used to normalize the BPD and ICG concentrations. For subcellular localization studies, FaDu cells were cultured overnight on 35 mm glass bottom dishes at a density of 75,000 cells per dish and incubated with free PS and nanodroplet formulations for 24 h. The cells were either stained with MitoTracker Green (M7514, Invitrogen) for 30 min or LysoTracker Green (DND-26, Invitrogen) for 60 min at 37 °C. The cells were later washed with PBS and stained with Hoechst prior to imaging with EVOS M7000 fluorescence imaging system using a 40x objective. Appropriate LED light cubes (Hoechst – DAPI light cube, MitoTracker and LysoTracker – GFP light cube, BPD – Qdot 705 light cube, ICG – Invitrogen Cy7 light cube) were used according to the fluorophore properties. Colocalization analysis of fluorescence images was performed in MATLAB [49]. The fluorescence images were binarized using Otsu threshold method. Within an image, pixels exhibiting both PS and the organelle tracker were assigned a value of 1 and summed to obtain the total number of colocalization pixels. The percent colocalization was calculated by dividing the total number of colocalization pixels to the total number of pixels that had PS fluorescence.

2.7. Phototoxicity of the nanodroplets

To test the toxicity of the nanodroplets, FaDu cells were seeded in 35 mm dish at a density of 1.5 × 10⁵ cells per dish. The following day, the cells were washed with PBS and fresh cell culture media containing free BPD and BPD-PFP at the concentration of 0.25 µM, 0.5 µM 1 µM,
2 μM, 5 μM, 10 μM. After 90 min of incubation, the media was replaced with fresh cell culture media and the cells were incubated for 24 h. The percentage of viable cells was calculated using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Thermofisher). The media was replaced with fresh cell culture media containing MTT (0.25 mg/mL) and incubated for 60 min. After the media was removed, formazan crystals formed in the cells were dissolved with DMSO, and absorbance was measured at 570 nm. The absorbance was normalized with untreated controls to obtain percent viability.

For evaluating photoxicity, FaDu cells were seeded in 35 mm dish at a density of 1.5 × 10⁵ cells per well. The following day, the cells were incubated with media containing BPD-PFP, ICG-PFP, BPD+ICG-PFP (with different loading ratios of BPD and ICG) and a liposomal formulation of BPD. The BPD concentration was maintained at 0.25 μM and ICG concentration was maintained at 1 μM. After 90 min of incubation, the media was replaced with fresh cell culture media and PDT was performed with a 690 nm laser at an irradiance of 150 mW/cm² and a total light dose of 1 and 2.5 J/cm². After PDT, the cells were incubated for 24 h, prior to assessing cell viability using the MTT assay.

2.8. Murine tumor models and in vivo therapy efficacy

All animal experiments were performed in compliance with the Institutional Animal Care and Use Committee (IACUC) of Massachusetts General Hospital (MGH) and Tufts University. Swiss nu/nu mice were raised in aseptic conditions in the institution’s animal facility with 12 h light and dark cycles, respectively. During the experiment, the animals were observed closely. Animals were humanely euthanized if they showed signs of pain/discomfort, their tumor reached 20 mm in any one dimension, or if their tumor became ulcerated.

The FaDu cells were collected by trypsinization, and the cells were suspended in a mixture of Matrigel and PBS in 1:1 v/v at a density of 1 million cells per 100 μL and injected subcutaneously into the mice. For determining the in vivo efficacy of the PFP, ICG-PFP, Visudyne (liposomal formulation of BPD used in clinics), BPD-PFP, BPD+ICG-PFP 1:1 and BPD+ICG-PFP 1:2 (0.5 mg/kg of BPD equivalent) were injected into mice via tail vein. The tumor was irradiated with a 690 nm laser at an irradiance of 40 mW/cm² and a total light dose of 100 J/cm² 90 min after systemic administration of the nanodroplets. The animals were monitored biweekly for up to 15 days, throughout which tumor volume was measured with 3D ultrasound imaging. For investigating the PDT response, tumors were treated with BPD+ICG-PFP 1:1 (0.5 mg/kg of BPD equivalent) and 690 nm laser with same irradiance and fluence as the previous experiment. Tumors were harvested 24 h later and embedded in optimal cutting temperature (OCT) compound for histological examination.

2.9. In vivo tumor oxygenation measurements

The oxygen sensor of the oxygen monitor system (Oxylite, Oxford Optronix Inc.) was inserted into the tumors using a 23-gauge sterile needle. Once the sensor was inserted into the tumor, it was left undisturbed until the pO₂ stabilized. The transducer was positioned to image a plane adjacent to the electrode to avoid any image artifacts. After 5 min, StO₂ PA imaging (750/850 nm; fluence of ~35 mJ) and PA imaging at 800 nm was performed. Then BPD+ICG-PFP 1:1 nanodroplets in PBS (1 mg/kg of BPD equivalent) were administered via tail vein injection without moving the mice or the transducer. The tumor oxygenation was monitored continuously throughout this procedure with both Oxylite and StO₂ PA imaging along with PA imaging at 800 nm for ICG contrast in the tumor. In a separate experiment, mice bearing FaDu xenografts were administered with PBS or BPD+ICG-PFP 1:1 via tail vein injection. After an interval of 30 min, pimonidazole (Hypoxprobe Inc.) was administered at a dose of 60 mg/kg and 60 min later the mice were euthanized. The tumors were then collected and embedded in OCT for histological examination of hypoxic regions.

2.10. In vivo fluorescence imaging of nanodroplet biodistribution

After the tumor oxygenation measurements, mice (under anesthesia) were scanned for ICG’s fluorescence using IVIS® Lumina Series III In Vivo imaging system (Perkin Elmer Inc) at different time intervals using 780 nm excitation filter and 840 nm emission filter. After the whole-body imaging, at 24 h post tail vein injection of nanodroplets, mice were euthanized, the tumor and other major organs (kidneys, liver, spleen, lungs, and heart) were harvested and imaged with the IVIS fluorescence imaging system to quantify ICG fluorescence. Auto-fluorescence and background were subtracted from each organ with data from an untreated mouse. Quantification of the fluorescence signal from the region of interest was performed using Living Image software (PerkinElmer).

2.11. Histology

The OCT embedded tumors were cryosectioned to obtain 10 μm thick sections that were stained with hematoxylin and eosin (H&E). For immunofluorescence (IF) staining, the cross sections were fixed in 1:1 acetone and methanol solution, air dried for 30 min, washed with PBS and blocked with SuperBlock blocking buffer (Thermo Scientific) for 30 min. Primary antibody (R&D Mouse/Rat CD31/PECAM-1 Polyclonal Goat IgG Cat: AF3628; 1:4 dilution) for targeting vasculature and antibody (Hypoxyprobe Red549 Kit HPI Cat: HP7–100; 1:50 dilution) against pimonidazole adducts was added to the sections and incubated overnight at 4 °C. Later, secondary antibody (NorthernLights™ Anti-goat IgG NL637 Cat: NL002; 1:50 dilution) was added to tissue sections and incubated for 2 h at room temperature. The sections were then washed in PBS and the nuclei were counterstained and mounted with DAPI SlowFade Gold Antifade Mountant (Thermo Scientific Cat: S36939). The slides were imaged with 20x objective using EVOS M7000 fluorescence imaging system. Throughout the acquisition and processing of all H&E and IF images, brightness and contrast levels were kept at the same level.

2.12. Statistical analysis

Data analysis was performed using GraphPad Prism 8. The results are reported as mean ± standard error of the mean (S.E.M). The specific statistical tests used on data are mentioned in the figure captions. P value less than 0.05 is considered statistically significant.

3. Results and discussion

3.1. Synthesis and characterization of PFP nanodroplets

PFP nanodroplets, regardless of ICG or BPD content, have hydrodynamic diameters of 204.5 nm ± 17.3 nm and a polydispersity index of 0.140 ± 0.022 (Data was obtained from 10 independent batches). The representative size distribution of the nanodroplets of all variations is shown in Fig. 1b. Although PFP have low boiling point (29 °C), the Laplace pressure imposed at the particle boundary makes PFP a superheated liquid at 37 °C. Because of the Laplace pressure, PFP remains stable even at physiological temperature (34-50 °C). Furthermore, the nanodroplets (fabricated with either single dye or both ICG and BPD) were stable in PBS for six weeks when stored at 4 °C and showed no significant change in their diameter (Fig. 1c). Fig. 1d shows display the absorption spectra of BPD-PFP (red solid line), ICG-PFP (green solid line) and BPD+ICG-PFP (black solid line) particles along with the absorption spectra of unbound free BPD and ICG (gray solid line) as a control reference. The characteristic peaks of BPD and ICG at 690 nm and 800 nm wavelengths were observed in BPD-PFP and ICG-PFP graphs, respectively. ICG in PFP shows a bathochromic shift due to the refractive...
index of the phospholipid coating and the close interaction between ICG molecules with PFP. The distinct peaks of BPD and ICG were observed in the spectra of BPD+ICG-PFP particles confirming the successful loading of the two dyes within our nanodroplets. The red shift of ICG remains which helps to spectrally differentiate BPD from ICG. PA signal generation is dependent on optical absorption properties of the tissue. As expected, the PA spectra of the nanodroplets are represented by black dots (Fig. 1d–f) that overlap with the absorption spectra. The characteristic peaks of BPD and ICG can also be distinguished through PA spectra in BPD+ICG-PFP solution.

3.2. Photoacoustic imaging of PFP nanodroplets

PA images (800 nm wavelength irradiation) of the nanodroplet solution placed in a tube are shown in Fig. 2a. We chose 800 nm wavelength irradiation as the nanodroplets have an absorption peak at this wavelength due to the presence of ICG. PFP and BPD-PFP (Fig. S1) showed very low PA signal, similar to the PBS control due to lack of ICG in the particles. On the other hand, ICG-PFP and BPD+ICG-PFP showed a large PA signal upon laser irradiation. Given that the top of the tube received the laser irradiation (due to reflection mode PA setup of Vevo LAZR system), high PA signal can only be observed in the specified top location. Furthermore, upon continuous imaging at 800 nm, we observed a gradual exponential decrease in the PA signal intensity. Fig. 2b shows the normalized PA signal for ICG-PFP and BPD+ICG-PFP (normalized to time t = 0 s). This exponential decrease in signal is due to the vaporization of PFP droplets achieved by exciting ICG. Previous study by Hannah et al., showed that the liquid to gas phase transition of ICG-PFP when excited with a laser pulse demonstrates with an initial increase in PA signal followed by decrease and stabilization of the PA signal.

![Fig. 2.](image)

3.3. Singlet oxygen production of PFP nanodroplets

PA images (800 nm wavelength irradiation) of the nanodroplet solution placed in a tube are shown in Fig. 2a. We chose 800 nm wavelength irradiation as the nanodroplets have an absorption peak at this wavelength due to the presence of ICG. PFP and BPD-PFP (Fig. S1) showed very low PA signal, similar to the PBS control due to lack of ICG in the particles. On the other hand, ICG-PFP and BPD+ICG-PFP showed a large PA signal upon laser irradiation. Given that the top of the tube received the laser irradiation (due to reflection mode PA setup of Vevo LAZR system), high PA signal can only be observed in the specified top location. Furthermore, upon continuous imaging at 800 nm, we observed a gradual exponential decrease in the PA signal intensity. Fig. 2b shows the normalized PA signal for ICG-PFP and BPD+ICG-PFP (normalized to time t = 0 s). This exponential decrease in signal is due to the vaporization of PFP droplets achieved by exciting ICG. Previous study by Hannah et al., showed that the liquid to gas phase transition of ICG-PFP when excited with a laser pulse demonstrates with an initial increase in PA signal followed by decrease and stabilization of the PA signal.
A high frame rate (20 frames/second) imaging system was utilized to capture the transient increase in PA signal. We were only able to capture the exponential decrease of PA signal post laser irradiation due to low frame rate (5 frames/second) of the system used in the study. Overall, our results were in agreement with the study by Hannah et al. [34].

Furthermore, ICG in free form (i.e., not encapsulated within PFP nanodroplets), PFP nanodroplets alone, or PFP nanodroplets in presence of BPD without ICG do not show this exponential decrease in PA signal at either 690 nm or 800 nm (Figs. S1 and S2b). This suggests ICG is crucial to burst open the nanodroplets to trigger the release of oxygen. To demonstrate that ICG in the PFP particles is not excited by the 690 nm laser (excitation peak for BPD), we repeated the experiment with 690 nm pulsed laser irradiation (Fig. 2c). The photoacoustic images obtained at 690 nm irradiation are shown in Fig. S2a. The PA signal for the control group, PFP alone, was very low and not statistically different from the baseline of PBS. The change in the PA signal at 690 nm wavelength irradiation for BPD-PFP, ICG-PFP and BPD+ICG-PFP were very minimal (Fig. S2b). Compared to the ~50% decrease of PA signal within 100 s of 800 nm pulsed irradiation, ICG-PFP and BPD+ICG-PFP showed less than 15% and 25% decrease in PA signal respectively, at 690 nm irradiation for the same amount of time. This decrease in PA signal is negligible and could be due to some minimal nanodroplet popping events as ICG has low absorption at this wavelength.

3.3. Generation of singlet oxygen by photoacoustic nanodroplets

SOSG is a commercially available probe known for its high sensitivity.
in detecting singlet oxygen species. SOSG fluoresces in the presence of singlet oxygen in an aqueous environment. BPD in free form as well as when encapsulated in the PFP nanodroplets had similar SOSG fluorescence with no irradiation and in the absence of SOSG. Upon irradiation, no significant differences in SOSG fluorescence increase were observed for free BPD and BPD-PFP in normal conditions, due to the abundant availability of oxygen in the environment. In contrast, BPD-PFP produced a significantly higher singlet oxygen as opposed to free BPD (Fig. 3a) in hypoxic environment (nitrogen bubbled PBS solution). ICG-PFP did not produce any singlet oxygen upon irradiation (Fig. 3).

Following the successful testing of BPD-PFP nanodroplets, the other nanodroplet variants with different ratio of ICG and BPD were tested for singlet oxygen production. The concentration ratio of the two different dyes, especially when being integrated in one nanoplatform is very important, as BPD and ICG have an overlapping absorption spectra around 690–720 nm wavelength range. In our previous work [48], we showed that BPD’s phototoxicity is not impacted by the presence of ICG when the dyes are in their free form (i.e., not encapsulated in nanoparticles). Here in Fig. 3b we show that the singlet oxygen production varies based on the BPD:ICG ratio. BPD and ICG were loaded into BPD–ICG–PFP nanodroplets with different starting concentrations ranging from 1:1 molar ratio of BPD:ICG to 1:4. We observed a significant decrease in the production of singlet oxygen when the nanodroplets were loaded with four times as much ICG as BPD. No significant differences were observed between BPD:ICG ratio of 1:1 or 1:2. This data highlights the importance of optimizing the ratio of dyes when encapsulating within a nan-entity, especially those with overlapping absorption spectra meant for PA guided PDT applications.

### 3.4. Cellular uptake of nanodroplets

We compared the uptake of free PS and nanodroplet formulations in FaDu cells. The nanodroplet incubation time was 90 min, similar to previous studies with Liposomal BPD formulations [53,54]. Quantitatively, we observed that BPD-PFP and BPD–ICG–PFP showed significantly higher uptake than free BPD (Fig. 4a) while free ICG and nanodroplet formulations of ICG had similar cellular uptake (Fig. 4b). BPD (free form) enters the cell via diffusion through the cell membrane [55,56]. In contrast, nanodroplets enter the cells via clathrin-mediated endocytosis, a common route for nanoparticles of size greater than 100 nm [57–60]. Given the differences in the mechanism of cellular uptake of BPD, we observe an increase in BPD uptake with nanodroplet formulation. On the other hand, ICG in free form also localizes in cells through clathrin-mediated endocytic pathway [61,62]. Hence, we do not observe any difference in the cellular uptake of ICG in free or nanodroplets formulations.

BPD (free form) localizes in mitochondria [63,64]. To evaluate cellular localization of BPD in nanodroplet formulations, we incubated cells with BPD-PFP, stained with MitoTracker, and performed fluorescence imaging (Fig. 5a). Free BPD and BPD-PFP showed strong fluorescence signal throughout the cell. The pseudo-colored yellow fluorescence signal on the merged image (Fig. 5a, column four) represents the colocalization of the MitoTracker green signal with the red BPD fluorescence signal, qualitatively indicating the uptake of BPD in the mitochondria. To determine the cellular localization of free ICG or its nanodroplets formulation, we stained cells incubated with free ICG or ICG–PFP with MitoTracker and LysoTracker and performed fluorescence imaging (Fig. 5b). Free ICG and ICG–PFP had punctate localization around the nucleus. Colocalization studies with both MitoTracker and LysoTracker showed that ICG localizes into both mitochondria and lysosomes at varying degrees as has been previously reported by others [65,66]. Moreover, the quantitative colocalization analysis indicated no significant difference (Table S1) in organelle localization of the dyes in free form or when encapsulated in PFP nanodroplets (Fig. S4).

![Image](attachment://Fig_6.png)

**Fig. 6.** a) Experiment timeline for phototoxic studies with PFP nanodroplets. b) Dark toxicity of the nanodroplets were subtracted from the light treated groups. BPD efficacy is largely not influenced by the presence of ICG except in the case of BPD–ICG–PFP 1:2 formulation. The results are expressed as mean ± S.E.M; Analysis was performed with two-way ANOVA with a Tukey’s multiple comparison test: ** = p < 0.01, **** = p < 0.0001.

### 3.5. BPD retains its phototoxicity in nanodroplets formulation

The dark toxicity of BPD-PFP nanodroplets is shown in Fig. S5a. Statistically significant cell death was observed with concentrations greater than 1 µM of BPD. Hence, to evaluate the phototoxicity of our nanodroplets we chose 0.25 µM concentration of BPD. The dark toxicity for all the PFP formulations is provided in Fig. S5b. The experiment timeline for the PDT study is provided in Fig. 6a. Empty PFP nanodroplets (Fig. 6b gray bars) had no toxicity. ICG-PFP (Fig. 6b green bar) did not cause any significant cell death at both the low or high light dose while BPD-PFP and BPD–ICG–PFP produced a dose dependent cell death (Fig. 6b red and dark blue bars respectively). Liposomal BPD, prepared similarly to Visudyne (the commercial product used in clinic), was
Fig. 8. PFP nanodroplets enhance tumor oxygenation and reduce hypoxia in the tumors. Measurements performed before and after injection of nanodroplets are shown in red and green color, respectively. a) Increase in StO$_2$ histogram of a representative tumor shown in Fig. 7. b) Average StO$_2$ increase in the tumor after oxygen filled PFP nanodroplet administration. c) Total hemoglobin levels quantified from StO$_2$ imaging shows no significant change in the accumulation of endogenous absorbers. Regional analysis of StO$_2$ shows that PFP nanodroplets significantly enhanced oxygen in d) low StO$_2$ areas while e) high StO$_2$ regions maintained similar levels as before nanodroplet administration. f) Validation of StO$_2$ imaging with oxygen sensor that was placed inside the tumor adjacent to the imaging plane. IF image of the tumor cross-section treated with g) control and treated with j) BPD+ICG-PFP 1:1 nanodroplets. The insets h, i and k show the tumor core at higher magnification with k) inset showing the core at higher magnification. l) Quantification of the hypoxic regions (ratio of pimonidazole positive area to total tumor area) from the IF image. The results are expressed as mean ± S.E.M; b, c, f, l = n = 3 mice; d & e, multiple regions within the 3 tumors. Scale bar = 1 mm for g and j. Scale bar = 100 µm for h, i and k; b-f: paired two-tailed t-test: * = p < 0.05, **** = p < 0.0001, l: unpaired two-tailed t-test: *** = p < 0.001. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
compared to various nanodroplet formulations. No statistically significant difference was observed among BPD-PFP, liposomal BPD or BPD+ICG-PFP 1:1 group indicating BPD cytotoxic effect was not compromised when encapsulated within the PFP nanodroplets. However, there was significant difference in cytotoxic effect when ICG loading was higher in the nanodroplet formulation (BPD+ICG-PFP 1:2, Fig. 6b orange bars). The difference in the phototoxicity of BPD+ICG-PFP nanodroplets with different loading ratios could be due to the interference of ICG with the availability of photons for BPD excitation for photodynamic action. Alternatively, the singlet oxygen species generated by BPD post light irradiation could have led to photooxidation of the ICG as has been reported previously in solutions and tissue phantoms [48,66–70] and ultimately reducing the singlet oxygen species available for cellular toxicity.

3.6. In vivo tumor oxygenation measurements

The oxygen delivery ability of the nanodroplets was demonstrated in a murine model with subcutaneous head and neck tumor xenografts. The ultrasound images show the subcutaneous tumor (identified by green generated by BPD post light irradiation could have led to photooxidation of the ICG as has been reported previously in solutions and tissue phantoms [48,66–70] and ultimately reducing the singlet oxygen species available for cellular toxicity.

3.6. In vivo tumor oxygenation measurements

The oxygen delivery ability of the nanodroplets was demonstrated in a murine model with subcutaneous head and neck tumor xenografts. The ultrasound images show the subcutaneous tumor (identified by green ROI in Fig. 7) as hypoechoic regions underneath the hyperechoic skin. The pre- and post nanodroplets injection images were obtained at the same cross-section as evident in the ultrasound images. The corresponding oxygen saturation map of the tumor is shown in Fig. 7 with blue and red regions corresponding to the hypoxic and oxygenated regions, respectively. An overall increase in the oxygenation of the tumor can be observed in the images, as evident from the greater abundance of red pseudo colored regions (oxygenated) after the administration of the PFP nanodroplets. We performed pixel-wise quantification of the StO2 in the tumor area and displayed the data as histogram in Fig. 8a. The histogram after PFP administration shifted towards the right, and also increased in total pixel count above 60% StO2. The average StO2 in the PFP administered mice had significant increase in the overall tumor oxygenation content (Fig. 8b). In contrast, the total hemoglobin levels in the tumor showed no significant difference indicating no accumulation of endogenous absorbers during the study (Fig. 8c).

To further understand the relative increase of oxygen in different regions of the tumor post nanodroplets administration, we quantified StO2 in multiple ROIs of area ~3.5 mm2. The mean StO2 of the tumors prior to nanodroplet administration was ~43%. Hence, we grouped the individual ROIs within the tumor based on pre-injection average StO2 values. The areas in the tumor whose StO2 was less than 43% in the pre-injection showed an increase in the StO2, whereas the highly oxygenated areas (SO2 > 43%) did not show an overall increase in the oxygenation (Fig. 8d and e). These results clearly indicate that our PFP nanodroplets are delivering oxygen to the hypoxic regions in the tumor. Finally, we validated the results of the StO2 PA imaging with an oxygen sensor (Oxylite) placed in the tumor adjacent to the imaging plane. The oxygen sensor directly measures the oxygen in the vicinity of the sensor tip and does not reflect the overall tumor oxygenation increase. Overall, a 9.1 ± 1.8 S.E.M fold increase in oxygen at the site of the sensor immediately after the administration and irradiation of the nanodroplets was observed proving that our nanodroplets supply oxygen to the hypoxic regions of the tumor that had an initial pO2 values of < 10 mmHg (Fig. 8f).

We performed histological examination to demonstrate the PFP nanodroplets ability to deliver oxygen and relieve hypoxia in tumors. Fig. 8g–k show the IF images of the control and BPD+ICG-PFP 1:1 treated tumor stained with DAPI for nuclei (blue), CD31 for vasculature (red) and pimonidazole for hypoxic regions (green). In the control tumor treated with only PBS (Fig. 8g), we can observe that pimonidazole signal (green) is more prevalent in the core of the tumor as expected. The zoomed insets clearly show the hypoxic areas present in regions away from the vasculature (Fig. 8h) as well around dysfunctional blood vessels (Fig. 8i). Post injection of the oxygenated nanodroplets, we observed a significant decrease in the tumor hypoxia. A representative IF image of a tumor injected with PFP droplets is shown in Fig. 8j. Very low pimonidazole signal can be seen here indicating a significant reduction in hypoxia. The core of the tumor region (Fig. 8k) had no pimonidazole signal, indicating our nanodroplets relieved hypoxia not only in non-functional vascular regions, but also to the core of the tumor. We quantified the IF images with a custom written MATLAB algorithm to calculate the pimonidazole positive areas and normalized with total tumor area. The quantification confirmed the qualitative observations that PFP nanodroplets can significantly reduce the hypoxic regions in the tumor (Fig. 8l).

In addition to the delivery of oxygen and BPD to the tumor, PFP nanodroplets are also good PA contrast agents due to ICG. The accumulation of PFP nanodroplets enhances the tumor contrast in PA imaging at 800 nm wavelength [47,48]. The increase in PA signal post PFP nanodroplets administration can be clearly seen in Fig. S6 marked by the white arrows. Quantification of the different regions of the tumor showed a significant increase in the PA contrast due to ICG after the administration of PFP nanodroplets (Fig. 9a). PFC compounds are also used as contrast agents for ultrasonography [71–74]. PFP nanodroplets also increased the ultrasound contrast in the tumor as expected. The enhancement of ultrasound contrast is clearly visible in Fig. 7. Furthermore, quantification of the ultrasound intensity per total tumor area showed statistically significant increase (25%) post injection of nanodroplets (Fig. 9b).

3.7. In vivo PDT efficacy of nanodroplets

Maximum ICG signal in the tumor occurred at 90 min post intravenous injection of the nanodroplets. (Fig. 10a). Hence, we chose a drug-light interval of 90 min for our in vivo PDT efficacy study. We also investigated the biodistribution of the nanodroplets 24 h post intravenous administration. Quantification of ex vivo fluorescence images (Fig. 10b and c) showed that the tumor had higher uptake of nanodroplets than all the major excised organs except liver. To investigate the PDT efficacy with oxygen enriched nanodroplets, mice were divided into multiple treatment groups as shown in Fig. 11a and b. PFP nanodroplets (no BPD or ICG) did not produce any therapeutic response as expected (Fig. 11b, gray line) and no statistically significant difference was observed between this group and the no-treatment control group (Fig. 11b, black line). ICG-PFP showed a moderate response to PDT at 690 nm irradiation (Fig. 11b, green line). Since ICG has a weak absorption at 690 nm, ICG could have been minimally excited and produced either a weak photothermal or PDT response at this wavelength.
Data for ICG-PFP group was shown only up to day 12 as the mice had to be euthanized as per veterinarian recommendation. BPD-PFP group (Fig. 11 a, red line) had better therapeutic response than the Visudyne (Fig. 11 a, cyan line) because of its greater singlet oxygen production ability due to the extra oxygen present in the nanodroplets.

We evaluated the treatment efficacy of nanodroplets fabricated with different loading ratios of BPD and ICG. In Fig. 11b, we demonstrate that BPD+ICG-PFP with 1:2 BPD:ICG loading ratio (Fig. 11b, orange line) did not produce any therapeutic response as it was not statistically different from the no-treatment control group (Fig. 11b, black line). This is in agreement with our in vitro data in Fig. 6 where the presence of higher ICG concentration in the nanodroplets significantly reduced the therapeutic efficacy of BPD. A possible mechanism could be the unavailability of photons for BPD’s photodynamic action as ICG’s molar extinction coefficient (36,483 M$^{-1}$ cm$^{-1}$ in water [76] and ~35,000 M$^{-1}$ cm$^{-1}$ in DMSO [48]) is approximately equal to BPD (34,895 M$^{-1}$ cm$^{-1}$ in DMSO [48]) at 687 nm. Alternatively, the singlet oxygen species generated by BPD post light irradiation could have led to photooxidation of the ICG as has been reported previously in solutions and tissue phantoms [48, 66–70] and ultimately reduced singlet oxygen species available for cytotoxicity. BPD and ICG concentration in the BPD+ICG-PFP 1:1 (Fig. 11b, blue line) was optimized to retain the BPD’s singlet oxygen
production and ICG’s PA signal response. BPD–ICG-PFP 1:1 (Fig. 11b, blue line) had a response similar to the BPD-PFP (Fig. 11a, red line) with no ICG (statistical information regarding the Fig. 11a and b are given in Tables S2 and S3). When incorporating multiple theranostic agents in a single carrier, it is important to optimize the loading concentration of different agents especially if they have similar optical absorption properties. The in vivo results for the BPD–ICG-PFP nanodroplets with different loading concentration complements the in vitro results obtained from our previous study [48]. In addition to investigating the efficacy of PFP nanodroplets in reducing tumor volume, we examined the acute effects of the treatment (24 h post treatment) in causing necrosis. The H&E image of a representative tumor cross-section in the control and BPD–ICG-PFP 1:1 group are shown in Fig. 11c and d. We can qualitatively envisage the necrosis imparted in the tumor by the oxygen loaded nanodroplets. The total necrotic area was quantified using a custom written MATLAB algorithm [77]. The tumors receiving BPD–ICG-PFP 1:1 with PDT treatment had ~50% necrotic volume and was significantly greater than the control group (Fig. 10e). Overall, here we demonstrated that the nanodroplets presented in this study have multiple-theranostic properties, i.e., they enhance tumor ultrasound contrast, enhance photoacoustic contrast, and deliver oxygen and photosensitizer for superlative PDT performance compared to the clinical formulation Visudyne.

4. Conclusions

In this work, we successfully designed a new nanoconstruct, PFP nanodroplets loaded with photosensitizer, which can combat hypoxia by delivering oxygen and improve PDT efficacy. Furthermore, these multimodal agents can not only deliver photosensitizer, but they can also be used to increase the contrast for photoacoustic and ultrasound imaging. We validated the ability of the nanodroplets to produce photoacoustic contrast, deliver oxygen, relieve hypoxia and improve PDT efficacy both in vitro and in vivo. In future studies, with aid of photoacoustic contrast provided by our engineered nanodroplets, we will explore the ability of nanodroplets to personalize PDT dose based on PS uptake, tumor vascularization and oxygenation content. Customizing PDT dose with these surrogate markers has previously shown to improve efficacy [7]. Our nanodroplets can also be used to increase oxygen content in other therapeutic strategies such as radiation and chemotherapy. Furthermore, these nanodroplets are made entirely from biocompatible and clinically approved materials that could potentially enable its transition to the clinic.

Author biography

Author Biography will be provided upon acceptance of the manuscript.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

The authors would like to gratefully acknowledge funds from the National Institutes of Health S10OD026844 (Mallidi), R41CA221420 and R41EY028639 (Cook and Mallidi). The authors thank Dr. Tayyaba Hasan for access to VisualSonics Vewo LZR system at Wellman Center for Photomedicine, Massachusetts General Hospital. Ms. Sophie Magidson for editing the manuscript for language, Drs. Girgis Obaid and Mohammad Saad at the Wellman Center for Photomedicine for their informative discussions on the experimental procedure, and Dr. Ryan Deschner and Mrs. Juili Kelvekar for their advice on the formulation.

Appendix A. Supporting information

Supplementary data associated with this article can be found in the online version at doi:10.1016/j.jpacs.2021.100306.

References

[1] J.P. Celli, B.Q. Spring, I. Rizvi, C.L. Evans, K.S. Samkoe, S. Verma, B.W. Pogue, T. Hasan, Imaging and photodynamic therapy: mechanisms, monitoring, and optimization, Chem. Rev. 110 (5) (2010) 2795–2838.
[2] S. Mallidi, B.Q. Spring, S. Chang, B. Vakoc, T. Hasan, Optical imaging, photodynamic therapy and optically triggered combination treatments, Cancer J. 21 (3) (2015) 194–205.
[3] R.M.A. Al-Delamey, H. Radhi, A. Farag, T. Al-Allaq, F. Vierde, R. Almadamgha, M. Al-Hadad, A. Fashih, A.F. Alani, M. Awida, Z. Alnajar, S.A.I. Alsamaraie, S. Elmasih, H. Mohammed, A. Yasin, Photodynamic therapy as a treatment option for oral cancer and dysplasia, Ann. Med. Health Sci. Res. 8 (2018) 59–64.
[4] W. Jerjes, T. Uiple, Z. Hamoon, C. Alexander Mosse, M. Morcos, C. Hopper, Photodynamic therapy outcome for T1/T2 N0 oral squamous cell carcinoma, Lasers Surg. Med. 43 (6) (2011) 463–469.
[5] N. Riguai, G. Shafirstein, M.T. Cooper, H. Baumann, D.A. Bellnier, U. Sunar, E.C. Tracy, D.J. Rohrbach, G. Wilding, W. Tan, M. Sullivan, M. Merziyan, B.W. Henderson, Photodynamic therapy with 3-(1-hexylthiolyloxy) pyropheophorbide a for cancer of the oral cavity, Clin. Cancer Res. 19 (23) (2013) 6605–6613.
[6] S. Mallidi, A.P. Khan, H. Liu, I. Daly, G. Rudd, P. Leon, S. Khan, B.M.A. Hussain, S. A. Hasan, S.A. Siddiqure, K. Akhtar, M. August, M. Troulis, F. Cuckov, J.P. Celli, T. Hasan, Platform for ergonomic intraoral photodynamic therapy using low-cost, modular 3D-printed components: design, comfort and clinical evaluation, Sci. Rep. 9 (1) (2019) 15830.
[7] B.C. Wilson, M.S. Patterson, L. Ilige, Implicit and explicit dosimetry in photodynamic therapy: a New paradigm, Lasers Med. Sci. 12 (3) (1997) 182–199.
[8] L. Cinccotta, D. Serto, E. Lampros, T. Hasan, A.H. Cinccotta, Benzoporphinone and benzophosphoin derivative combination phototherapy effectively eradicates large murine sarcoma, Photochem. Photobiol. 63 (2) (1996) 229–237.
[9] J.M. Brown, W.B. Wilson, Exploiting tumor hypoxia in cancer treatment, Nat. Rev. Cancer 4 (6) (2004) 437–447.
[10] K. Graham, E. Unger, Overcoming tumor hypoxia as a barrier to radiotherapy, chemotherapy and immunotherapy in cancer treatment, Int. J. Nanomed. 15 (2020) 6049–6058.
[11] P. Vauzel, A. Mayer, Hypoxia in cancer: significance and impact on clinical outcome, Cancer Metastasis Rev. 26 (2) (2007) 225–239.
[12] M. Hockel, P. Vauzel, Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects, J. Natl. Cancer Inst. 93 (4) (2001) 266–276.
[13] F. Tomasielli, A. Maier, H. Pinter, H. Stranzl, F.M. Smolle-Juttner, Photodynamic therapy enhanced by hyperbaric oxygen in acute endoluminal palliation of malignant bronchial stenosis (clinical pilot study in 40 patients), Eur. J. Cardiothorac. Surg. 19 (5) (2001) 549–554.
[14] A. Maier, U. Anegg, B. Fell, P. Rehak, B. Ratzenhofer, F. Tomasielli, O. Sankin, H. Pinter, F.M. Smolle-Juttner, G.B. Frietsch, Hyperbaric oxygen and photodynamic therapy in the treatment of advanced carcinoma of the cardio and the esophagus, Lasers Surg. Med. 26 (3) (2000) 308–315.
[15] A. Maier, U. Anegg, F. Tomasielli, P. Rehak, O. Sankin, B. Fell, H. Renner, H. Pinter, F.M. Smolle-Juttner, G.B. Frietsch, Does hyperbaric oxygen enhance the effect of photodynamic therapy in patients with advanced esophageal carcinoma? A Clinical pilot study, Endoscopy 32 (1) (2000) 42–48.
[16] J.M. Clark, C.J. Lambertsen, Pulmonary oxygen toxicity: a review, Pharmacol. Rev. 23 (2) (1971) 37–133.
[17] S.R. Thor, Hyperbaric oxygen: its mechanisms and efficacy, Plast. Reconstr. Surg. 127 (Suppl 1) (2011) 1315S–1415S.
[18] M. Heyboer 3rd, D. Sharma, W. Santiago, N. McCulloch, Hyperbaric oxygen therapy: side effects defined and quantified, Adv. Wound Care 6 (6) (2017) 210–224.
[19] Y. Sheng, H. Nesbitt, B. Callan, M.A. Taylor, M. Love, A.P. McHale, J.F. Callan, Oxygen generating nanoparticles for improved photodynamic therapy of hypoxic tumours, J. Control Release 264 (2017) 333–340.
[20] S. Gao, G. Wang, Z. Qin, X. Wang, G. Zhao, Q. Mu, L. Zhu, Oxygen-generating hybrid nanoparticles to enhance fluorescent/photoacoustic/ultrasound imaging guided tumor photodynamic therapy, Biomaterials 112 (2017) 324–335.
[21] J.J. Kwan, M. Kaya, M.A. Borden, P.A. Dayton, Theranostic oxygen delivery using ultrasound and microbubbles, Theranostics 2 (12) (2012) 1174–1184.
[22] J.R. Eisenbrey, R. Shraim, J.-B. Liu, J. Li, M. Stanczak, B. Oeffinger, D.B. Leeper, S. Mallidi, M. Xavierselvan et al.

Photoacoustics 25 (2022) 100306
A combination of visudyne and a lipid-anchored liposomal formulation of benzoporphyrin derivative enhances photodynamic therapy efficacy in a 3D model.

2. A preliminary study, PLoS One 13 (4) (2018), e0199667.

3. Y.-Z. Zhao, L.-N. Du, C.-T. Lu, Y.-G. Jin, S.-P. Ge, Potential and problems in ultrasound-responsive drug delivery systems, Int. J. Nanomed. 8 (2013) 1621–1633.

4. M. Kuriakose, M.A. Borden, Microbubbles and nanodroplets for photoacoustic tomography, Curr. Opin. Collid Interface Sci. 15 (2011), 101–104.

5. M. Kuriakose, A. Londino, J. Slezak, M. Xu, L.V. Wang, Photoacoustic imaging in biomedicine, Rev. Sci. Instrum. 77 (4) (2006) 483–487.

6. Y. Cheng, H. Cheng, C. Jiang, X. Qiu, K. Wang, W. Huan, A. Yuan, J. Wu, Y. Hu, Perfluorocarbon nanoparticles enhance reactive oxygen levels and tumour growth inhibition in phototherapy, Nat. Commun. 6 (2015) 7885.

7. S. Mallidi, Z. Silber, A.L. Bulin, L.Z. Petrovic, M. Xavierselvan, M. Kuriakose, M.D. Kennedy, C.D. Nguyen, J. S. Mallidi, G.P. Luke, S. Emelianov, Photoacoustic imaging in cancer detection, Photoacoustics 25 (2022) 100306.

8. M. Kuriakose et al., Controlled and G. Obaid, S. Bano, S. Mallidi, M. Broekgaarden, J. Kuriakose, Z. Silber, A.L. Bulin, L.Z. Petrovic, M. Xavierselvan, M. Kuriakose, M.D. Kennedy, C.D. Nguyen, J. S. Mallidi, G.P. Luke, S. Emelianov, Photoacoustic imaging in cancer detection, Photoacoustics 25 (2022) 100306.

9. N. Onda, R. Mizutani-Morita, S. Yamashita, R. Nagahara, S. Matsumoto, T. Yoshida, M. Shibutani, Fluorescence contrast-enhanced proliferative lesion imaging by enema administration of indocyanine green in a rat model of colon carcino-cgenesis, Oncotarget 8 (52) (2017) 90278–90296.

10. C. Abels, S. Fickweiler, P. Weiderer, W. Baumler, F. Hofstadter, M. Landthaler, R. M. Szeimies, Indocyanine green (ICG) and laser irradiation induce photooxidation, Arch. Dermatol. Res. 292 (8) (2000) 404–411.

11. D. Kessel, Y. Luo, Mitochondrial photodamage and PDT-induced apoptosis, J. Photochem. Photobiol. B 58 (2000) 98–995.

12. Z. Wang, X. Geng, J. Li, H. Wang, X. Xu, X. Li, X. Sha, Z. Zhang, Oxygen-delivering polyfluorocarbon nanovehicles improve tumor oxygenation and potentiate photo-oxidative-mediated antitumor immunity, ACS Nano (2021).

13. F. M. Penha, E. B. Rodrigues, M. Maia, C. H. Meyer, E. de Paula Fiod Costa, E. Dib, N. Onda, R. Mizutani-Morita, S. Yamashita, R. Nagahara, S. Matsumoto, T. Yoshida, M. Shibutani, Fluorescence contrast-enhanced proliferative lesion imaging by enema administration of indocyanine green in a rat model of colon carcino-cgenesis, Oncotarget 8 (52) (2017) 90278–90296.

14. C. Abels, S. Fickweiler, P. Weiderer, W. Baumler, F. Hofstadter, M. Landthaler, R. M. Szeimies, Indocyanine green (ICG) and laser irradiation induce photooxidation, Arch. Dermatol. Res. 292 (8) (2000) 404–411.

15. D. Kessel, Y. Luo, Mitochondrial photodamage and PDT-induced apoptosis, J. Photochem. Photobiol. B 58 (2000) 98–995.

16. Z. Wang, X. Geng, J. Li, H. Wang, X. Xu, X. Li, X. Sha, Z. Zhang, Oxygen-delivering polyfluorocarbon nanovehicles improve tumor oxygenation and potentiate photodynamic-mediated antitumor immunity, ACS Nano (2021).

17. A. Funovic, R. Weisleder, C.H. Tung, Protease sensors for bioimaging, Anal. Bioanal. Chem. 377 (6) (2003) 956–963.

18. A. Becher, S. Reindl, A. Penzkofer, S.H. Gong, M. Landthaler, R.M. Szeimies, C. Abels, W. Baumler, Quantum yield of triplet formation for indocyanine green, J. Photochem. Photobiol. B 105 (1) (2001) 65–71.

19. G. D. Santiesteban, K.A. Hallam, S.K. Yarmoska, S.Y. Emelianov, Color-coded microbubbles, J. Control Release 138 (3) (2009) 268–272.

20. D. Kessel, Y. Luo, Mitochondrial photodamage and PDT-induced apoptosis, J. Photochem. Photobiol. B 58 (2000) 98–995.

21. D. Santiesteban, K. Hallam, S. Yarmoska, S. Emelianov, Indocyanine green-based contrast agent for photoacoustic and fluorescence imaging guided breast cancer therapy, ACS Biomater. Sci. Eng. 7 (2) (2021) 250–259.

22. D. Kessel, Y. Luo, Mitochondrial photodamage and PDT-induced apoptosis, J. Photochem. Photobiol. B 58 (2000) 98–995.

23. A. Scardovi, I. Rizvi, G. Obaid, S. Bano, T. Hasan, D. Kessel, Photodynamic therapy: promoting in vitro efficacy of photodynamic therapy by liposomal formulations of a photosensitizing agent, Lasers Surg. Med. 50 (5) (2018) 499–505.

24. I. Rizvi, G. Obaid, S. Bano, T. Hasan, D. Kessel, Photodynamic therapy: promoting in vitro efficacy of photodynamic therapy by liposomal formulations of a photosensitizing agent, Lasers Surg. Med. 50 (5) (2018) 499–505.

25. B. R Ram, M. LaFay, K. Nottberg, M. Ghorbani, M. Funovic, R. Weisleder, C.H. Tung, Protease sensors for bioimaging, Anal. Bioanal. Chem. 377 (6) (2003) 956–963.

26. G. Kim, S.W. Huang, K.C. Day, M. O’Donnell, R.R. Agayan, M.A. Day, R. Kopelman, S. Ashkenazi, Indocyanine-green-embedded PEBBLEs as a contrast agent for photoacoustic imaging, J. Biomed. Opt. 12 (4) (2007), 044020.

27. D. Kessel, Y. Luo, Mitochondrial photodamage and PDT-induced apoptosis, J. Photochem. Photobiol. B 58 (2000) 98–995.

28. Y. Wang, Z. Mai, W. Jin, D. Simeone, T. Hasan, Impacting pancreatic cancer therapy in heterotypic in vitro organoids and in vivo tumors with specificity-tuned, Y. Wang, Z. Mai, W. Jin, D. Simeone, T. Hasan, Impacting pancreatic cancer therapy in heterotypic in vitro organoids and in vivo tumors with specificity-tuned.
Marvin Xavierselvan is a 3rd year Ph.D. student in the integrated Biofunctional Imaging and Therapeutics Lab (iBIT) at Tufts University. He has experience in designing biomedical instrumentation, photoacoustic imaging and photodynamic therapy. His research is focused on utilizing photoacoustic imaging and photodynamic therapy to treat therapy resistant tumors. He received several travel awards and best poster awards at national and international conferences. His scientific interests are photoacoustic imaging, image guided PDT in head and neck cancer, and pancreatic cancer.

Dr. Jason Cook received his B.S. in Biomedical Engineering from the University of Tennessee and both his M.S. and Ph.D. in Biomedical Engineering from the University of Texas at Austin. Dr. Cook’s professional career has been centered on the development and commercialization of delivery and capture technology for diagnosis and therapeutics, with an emphasis on nanotechnology. Dr. Cook is currently the Chief Technology Officer of Bluejay Diagnostics, Inc, a commercial-stage medical device company focusing on in-vitro diagnostics. Dr. Cook is also the CEO of NanoHybrids, Inc., a nanoparticle manufacturer and pre-clinical stage company based in Austin, TX.

Jeanne Duong is a Junior undergraduate student in the Biomedical Engineering Department at Tufts University. She started working in the integrated Biofunctional Imaging and Therapeutics (iBIT) Lab from January 2021. Her research interests are photoacoustic imaging, immunofluorescence procedures, cancer theranostics and image co-registration.

Nashielli Diaz is a Senior undergraduate student in the Biomedical Engineering Department at Tufts University. She joined the integrated Biofunctional Imaging and Therapeutics (iBIT) Lab in Spring ‘21 and has research interests in light based cancer theranostics, photodynamic therapy, hypoxia and metastasis.

Dr. Dr. Kimberly Homan received her B.S. in Chemical Engineering from the University of Arizona and both her M.S. and Ph.D. in Biomedical Engineering from the University of Texas at Austin. Her graduate work in biomedical imaging and nanoparticles helped lead to the formation of NanoHybrids Inc, based in Austin TX, which she co-founded. Concurrently, she did a postdoc at the Wyss Institute in Harvard University focused on 3D bioprinting and organ-on-chip technologies. She is now the Director of the Complex in vitro Systems group at Genentech in South San Francisco, CA.

Dr. Srivalleesha Mallidi received her Masters and PhD Degree in Biomedical Engineering from the University of Texas at Austin. Her graduate work was on molecular specific photoacoustic imaging to understand nano-molecular interactions. After graduation, she joined Wellman Center for Photomedicine (WCP) at Massachusetts General Hospital (MGH), Harvard Medical School with a goal to translate the imaging techniques to clinic, and was a NIH Ruth L. Kirschstein post-doctoral fellow. She won several travel awards, poster awards and Young Investigator award at national and international conferences. Currently Dr. Mallidi is an Assistant Professor at Department of Biomedical Engineering at Tufts University, Medford, MA and she directs the integrated Biofunctional imaging lab that focuses on ultrasound and photoacoustic imaging based therapeutic strategies.